•  
  •  
 

Abstract

The current study aimed to biosynthesize silver nanoparticles (AgNPs) by extracellular metabolites of marine Kocuriaflava, and characterization it, then use them to enhance the ciprofloxacin activity against MDR pathogenic bacteria. The seawater was collected from the Iraqi Marine Water in January 2022. The isolate K.flava (F57) was identified by morphological, some biochemical, and molecular identification by 16SrDNA amplification and sequencing. The identity (%) of the F57 16SrDNA gene with those in GenBank was 99.93%, and the phylogenetic tree showed high identity with K.flava strain AUMC B-459. GC/MS spectrometry of the F57 extract revealed the presence of thirty compounds. The extracellular metabolites of F57 are used to biosynthesize of AgNPs., and the production of AgNPs was verified by UV–Vis spectroscopy, FTIR- spectrum, XRD, FESEM, and EDX analysis. The antimicrobial activity of AgNPs was investigated against Klebsiellapneumoniae, Pseudomonasaeruginosa, Staphylococcushaemolyticus, and two isolates of Escherichiacoli (1&2), the results showed that AgNPs were effective against these pathogens. The minimal inhibitory concentration (MIC) of AgNPs, ciprofloxacin, and their combination was investigated against these MDR pathogens. The lowest MIC of AgNPs. was 7.81~μg/ml against P.aeruginosa. All pathogenic bacteria were resistant to ciprofloxacin. The combination of ciprofloxacin and AgNPs had a synergistic effect on P.aeruginosa, S.haemolyticus, and E.coli (2). The isolates E.coli (1&2) became sensitive to ciprofloxacin after being mixed with AgNPs. So, the biosynthesized AgNPs. by extracellular metabolites of marine K.flava had antimicrobial properties and contributed to enhancing the effectiveness of ciprofloxacin.

Keywords

AgNPs, Antibiotic enhancement, Ciprofloxacin, Kocuria flava, MDR

First Page

507

Last Page

525

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Receive Date

10-16-2023

Revise Date

2-2-2024

Accept Date

2-4-2024

Share

COinS